This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

Semaglutide can mitigate antipsychotic-induced metabolic dysfunction in patients with schizophrenia, prediabetes, and overweight or obesity on second-generation antipsychotics.

GLP-1 RAs were first approved for youth with type 2 diabetes with liraglutide (Victoza) in 2019, followed by semaglutide (Wegovy) and dulaglutide (Trulicity) in 2022. Prior to these approvals, insulin ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

Mounjaro - the brand name for tirzepatide - has become one of the most talked-about medications in metabolic health, and for good reason. But the conversation around it has gotten tangled up with ...